Hoth Therapeutics
HOTH

$1.06

22.22%

Market Cap: $7.32M

About: Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Employees: 3

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

10% more funds holding

Funds holding: 10 [Q1] → 11 (+1) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

5.07% less ownership

Funds ownership: 11.57% [Q1] → 6.51% (-5.07%) [Q2]

58% less capital invested

Capital invested by funds: $765K [Q1] → $317K (-$447K) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$4

277%

upside

Avg. target

$4.40

315%

upside

High target

$5

372%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

EF Hutton Jason Kolbert 38% 1-year accuracy 10 / 26 met price target	372%upside $5	Buy Maintained	5 Sept 2024
EF Hutton Jason Kolbert 38% 1-year accuracy 10 / 26 met price target	372%upside $5	Buy Assumed	21 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target	277%upside $4	Buy Reiterated	16 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target	277%upside $4	Buy Reiterated	26 Jul 2024
HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 121 / 288 met price target	277%upside $4	Buy Reiterated	22 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about HOTH published over the past 30 days

Zacks Investment Research

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial NEW YORK , Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Cancer Patient Ceased Treatment After One Week Due to Rapid Success In the reported case, the patient, a 59-year-old female undergoing treatment at George Washington University for metastatic breast cancer, experienced significant improvement in symptoms just one week after initiating HT-001 therapy. Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment after just seven days.

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Aronnax to Determine the Maximum-Tolerated Dose (MTD) Post Intravenous Injection Followed by a Dose Range-Finding Phase of Hoth's Orphan Drug HT-KIT NEW YORK , Aug. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer therapeutic. HT-KIT research, which was conducted at NC State University to evaluate the efficacy of HT-KIT in cancerous and non-cancerous cells, has demonstrated that HT-KIT effectively kills human mast cells that rely on signaling through the KIT receptor to survive.

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Why Is Hoth Therapeutics (HOTH) Stock Moving Today?

Hoth Therapeutics (NASDAQ: HOTH ) stock is on the move Wednesday after the clinical-stage biopharmaceutical company announced a new partnership with LTS Therapy Systems. This partnership has the two companies working together to accelerate the development of Hoth Therapeutics' candidate for Alzheimer's disease.

Why Is Hoth Therapeutics (HOTH) Stock Moving Today?

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients. HT-ALZ's pre-clinical significance lies in its ability to demonstrate marked cognitive improvement and quality of life for subjects suffering from Alzheimer's disease The pre-clinical research shows compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment.

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Three New Sites Join HT-001 Trial, GW University Hospital, UC Irvine and Northwell Health NEW YORK , July 16, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a patient-focused biopharmaceutical company, today announced that it has received written approval from the GW University Hospital, UC Irvine and Northwell Health to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). "We are very pleased to have received approval from these three world class medical centers for our FIH clinical trial," said Hoth Therapeutics Chief Executive Officer, Robb Knie.

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Nvidia BioNeMo generative AI platform will be used to accelerate the training of models on proprietary data NEW YORK , June 10, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvidia. BioNeMo provides researchers and developers a fast and easy way to build and integrate state-of-the-art generative AI applications across the entire drug discovery pipeline—from target identification to lead optimization—with AI workflows.

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

NEW YORK , May 1, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the EF Hutton Annual Global Conference in New York, NY. To learn more about the EF Hutton Annual Global Conference please visit https://efhutton.com/conference/.

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

NEW YORK , March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of the Company originally issued in January 2023, having an exercise price of $5.00 per share, at a reduced exercise price of $1.6775 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (No.

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

See News Rankings